Ebook: Tamoxifen: Pioneering Medicine in Breast Cancer
- Tags: Cancer Research, Pharmacology/Toxicology, Oncology, Endocrinology
- Series: Milestones in Drug Therapy
- Year: 2013
- Publisher: Springer Basel
- Edition: 1
- Language: English
- pdf
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Content:
Front Matter....Pages i-xxii
Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens....Pages 1-30
Tamoxifen Goes Forward Alone....Pages 31-46
Metabolites of Tamoxifen as the Basis of Drug Development....Pages 47-67
Adjuvant Therapy: The Breakthrough....Pages 69-84
The Wisconsin Story in the 1980s: Discovery of Target Site-Specific Estrogen Action....Pages 85-99
Carcinogenesis and Tamoxifen....Pages 101-114
Chemoprevention: Cinderella Waiting for the Ball....Pages 115-134
Tamoxifen and Raloxifene Head to Head: The STAR Trial....Pages 135-142
Acquired Resistance to Tamoxifen: Back to the Beginning....Pages 143-163
The Legacy of Tamoxifen....Pages 165-178
Back Matter....Pages 179-199
Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years.
This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
Content:
Front Matter....Pages i-xxii
Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens....Pages 1-30
Tamoxifen Goes Forward Alone....Pages 31-46
Metabolites of Tamoxifen as the Basis of Drug Development....Pages 47-67
Adjuvant Therapy: The Breakthrough....Pages 69-84
The Wisconsin Story in the 1980s: Discovery of Target Site-Specific Estrogen Action....Pages 85-99
Carcinogenesis and Tamoxifen....Pages 101-114
Chemoprevention: Cinderella Waiting for the Ball....Pages 115-134
Tamoxifen and Raloxifene Head to Head: The STAR Trial....Pages 135-142
Acquired Resistance to Tamoxifen: Back to the Beginning....Pages 143-163
The Legacy of Tamoxifen....Pages 165-178
Back Matter....Pages 179-199
....